

Excision BioTherapeutics, a developer of potentially curative CRISPR anti-viral therapies to improve patient lives, has closed $60 million financing. GreatPoint Ventures led the round.
Source: Press Release
Excision BioTherapeutics, a developer of potentially curative CRISPR anti-viral therapies to improve patient lives, has closed $60 million financing.
Excision BioTherapeutics, a developer of potentially curative CRISPR anti-viral therapies to improve patient lives, has closed $60 million financing. GreatPoint Ventures led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination